^
Association details:
| Biomarker: | HER-2 exon 20 insertion |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Hyrnuo (sevabertinib) (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1320MO - Early evidence of efficacy in patients (pts) with non-small cell lung cancer (NSCLC) with HER2 exon20 insertion (ex20ins) mutations treated in a phase I study with BAY 2927088
Published date:
10/16/2023
Excerpt:
Of note, the ORR was 60%, including 1 complete response, 8 PR and 3 uPR, in 20 evaluable pts with HER2 ex20ins mutant disease...In pts with HER2 ex20ins mutant disease, BAY 2927088 showed encouraging preliminary anti-tumour activity. These results warrant further investigation of BAY 2927088 in pts with NSCLC.
Trial ID: